Compare YSXT & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | CABA |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 200.2M |
| IPO Year | 2024 | 2019 |
| Metric | YSXT | CABA |
|---|---|---|
| Price | $1.55 | $2.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 824.8K | ★ 2.3M |
| Earning Date | 07-31-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $71,452,736.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.08 | ★ N/A |
| Revenue Growth | ★ 22.04 | N/A |
| 52 Week Low | $1.25 | $0.99 |
| 52 Week High | $9.96 | $3.67 |
| Indicator | YSXT | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 30.97 | 48.21 |
| Support Level | $1.25 | $2.32 |
| Resistance Level | $2.45 | $2.70 |
| Average True Range (ATR) | 0.32 | 0.18 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 20.83 | 50.00 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.